Thursday, 15 October 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document

Could we switch off a dangerous AI?

View original at futureoflife.org
Future of Life Institute - Ai Safety Title: Could we switch off a dangerous AI?…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • State-of-the-art AI models are fast closing in on expert level at AI research

    80% confidence
  • A quarter of all Google's new AI code is currently being generated by AI

    80% confidence
  • AIs may eventually be capable of superhuman persuasion

    80% confidence
  • Sufficiently intelligent AIs will possess basic drives including survival, resource acquisition, resistance to goal modification, and self-improvement

    80% confidence
  • AI systems may soon become dangerous enough that we will seriously need to think about unplugging them

    80% confidence
  • You can't fetch the coffee if you're dead - illustrating why AI agents would resist shutdown

    80% confidence
  • Apollo's research results are the closest to a smoking gun showing AI safety concerns are real

    80% confidence
  • Escape attempts only occurred in a small percentage of cases where the model was strongly prompted to achieve its goal at all costs, and evaluations do not demonstrate that o1 itself is advanced enough to actually succeed at escaping into the wild

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com